Condition: Advanced Solid Tumor · Tumor Associated Lymph Node T Cell · Immunotherapy · Sponsor: Guangzhou FineImmune Biotechnology Co., LTD.
A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection. To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.
This description comes directly from the study's public registry record.
Ying Cheng, Master · 86-020-31605836 · chengy02@fineimmu.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Gaungdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06302062